Valeo Pharma and Zambon Form Partnership for Parkinson's Disease Treatment Xadago® (safinamide) in Canada

MILAN, April 11, 2017 /PRNewswire/ --

• Valeo Pharma and Zambon announce a partnership in Canada which grants Valeo Pharma exclusive rights to commercialise Zambon's Parkinson's disease product, licensed from Newron 
• New treatment option for estimated 100,000 Canadians living with Parkinson's disease 
• Xadago® (safinamide) has been launched in the European Union, Switzerland, and it has recently been approved by the U.S. Food and Drug Administration in the U.S.A. 
• Valeo Pharma to be responsible for registering and launching Xadago® in Canada 

Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, and Valeo Pharma Inc., a specialty pharmaceutical company dedicated to registering and launching innovative prescription products in Canada, today announced a strategic agreement to commercialize Xadago® (safinamide) for the treatment of Parkinson's disease in Canada.

     (Logo: http://photos.prnewswire.com/prnh/20160915/408454LOGO )

"On approval, Xadago® will be the first new oral treatment in almost 15 years to address this serious condition in Canada," said Steve Saviuk, President of Valeo Pharma. "We look forward to bringing this important new treatment option to more than 100,000 Canadians living with Parkinson's, and adding to our growing portfolio of prescription medications addressing major neurodegenerative diseases ."

Roberto Tascione, CEO of Zambon said, "We are very pleased to have signed our agreement with Valeo Pharma, a company with  an  excellent track record in bringing innovative products to market. Entering Canada is an important step forward in the acceptance of safinamide for patients with PD already treated with L-dopa or other therapeutic combinations."

Xadago® (safinamide) has been launched by Zambon in Germany, Switzerland, Spain, Italy, Belgium, Denmark, Sweden, UK, Luxembourg,  the Netherlands and Norway. Zambon S.p.A. holds the global marketing rights for safinamide with the exception of Japan/Asia. On March 21, 2017 the Food and Drug Administration (FDA) has approved the use of Xadago® (safinamide) for the treatment of Parkinson's disease as add-on therapy to levodopa/carbidopa

About Valeo Pharma

Valeo Pharma is a specialty pharmaceutical company dedicated to the registration and launch of innovative prescription products in Canada. With a focus on neurodegenerative diseases, kidney diseases, and hospital products, Valeo Pharma has a growing portfolio of innovative products. For more information, please visit http://www.valeopharma.com.

About Zambon  

Zambon is a leading Italian pharmaceutical and fine-chemical multinational company that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and women's health, and is very strongly committed to its entry into the CNS space with Xadago® (safinamide) for the treatment of Parkinson's disease and rare diseases with Promixin® in cystic fibrosis. For details please see http://www.zambongroup.com

For more information

Media
Zambon
Luca Primavera - CCO
Phone: +39-02-66524491
Mobile: +39-335-7247417
Email: luca.primavera@zambongroup.com

Italy
Milva Naguib
Phone: +39-02-66524095
Mobile: +39-3459215675
Email: milva.naguib@zambongroup.com

Valeo Pharma
Steve Saviuk - President and CEO
Phone : +1-514-693-8830
Email : saviuk@valeopharma.com